Loading...
NPI 1154307635 · Las Vegas, NV · Interventional Pain Medicine Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Stephen Gephardt is a interventional pain medicine physician provider located in Las Vegas, Nevada. This profile covers 35 Medicare and 9 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Stephen Gephardt |
| Address | 7220 S Cimarron Rd Ste 270 |
| City | Las Vegas |
| State | NV |
| ZIP | 89113 |
| Taxonomy | Interventional Pain Medicine Physician |
| NPI Enumerated | December 16, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $387.4K |
| Medicaid | $70K |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
35 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,980 | $90 | $184K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 340 | $150 | $51.5K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 240 | $60 | $14.2K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 2,800 | $10 | $14K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 180 | $70 | $11.9K |
| 64635 | Under fluoroscopic or CT guidance, the provider applies an agent to a lower back joint to destroy nerve tissue. | 50 | $220 | $10.8K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 80 | $120 | $10.4K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 50 | $200 | $9.9K |
| 64483 | This procedure is the injection of an anesthetic agent and/or steroid in the form of a transforaminal epidural injection into a single level (either lumbar or sacral). | 80 | $110 | $9K |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | 320 | $30 | $8.6K |
Showing 1–10 of 35
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 35 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
35 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| G0481 | 5 | 20 | 130 | $150 | $74.5K |
| J0585 | 27 | 30 | 5,760 | $1 | $44.8K |
| G0482 | 10 | 20 | 40 | $190 | $32.8K |
| 64635 | 24 | 80 | 40 | $440 | $25.2K |
| 80307 | 29 | 110 | 100 | $60 | $21.9K |
| 64483 | 30 | 100 | 60 | $230 | $20.3K |
| 99214 | 14 | 3,610 | 110 | $80 | $19K |
| 64493 | 36 | 80 | 50 | $210 | $17.1K |
| 64633 | 16 | 30 | 30 | $450 | $16.2K |
| 99215 | 484 | 790 | 40 | $120 | $12.2K |
Showing 1–10 of 35
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
9 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 670 | $70 | $49K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 630 | $30 | $17.7K |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 150 | $10 | $1.4K |
| 82570 | The lab analyst measures the amount of creatinine, in a patient specimen, other than blood. Creatinine is the waste material generated by the muscle tissue produced from the breakdown of creatine… | 650 | $1 | $1.3K |
| 20553 | Trigger point injection, or TPI, is a medical procedure in which the provider injects an anesthetic or corticosteroid substance into three or more muscles to relieve painful areas or knots in muscles… | 30 | $10 | $360 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 140 | $1 | $140 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 140 | $1 | $140 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 30 | $1 | $100 |
| 80377 | The lab analyst measures the presence or amount of seven or more definitive drugs in the patient specimen. | 10 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
9 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 98 | 150 | 1,440 | $20 | $193.7K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 778 | 2,250 | 290 | $60 | $138K |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 198 | 360 | 190 | $10 | $26.9K |
| 20553 | Trigger point injection, or TPI, is a medical procedure in which the provider injects an anesthetic or corticosteroid substance into three or more muscles to relieve painful areas or knots in muscles… | 20 | 30 | 80 | $20 | $21.4K |
| 82570 | The lab analyst measures the amount of creatinine, in a patient specimen, other than blood. Creatinine is the waste material generated by the muscle tissue produced from the breakdown of creatine… | 17 | 40 | 530 | $1 | $6.1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 94 | 140 | 440 | $1 | $2.8K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 60 | 80 | 100 | $1 | $1.4K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 24 | 50 | 160 | $1 | $1.4K |
| 80377 | The lab analyst measures the presence or amount of seven or more definitive drugs in the patient specimen. | 5 | 10 | 90 | $0 | $0 |
Other providers in the same ZIP code as Stephen Gephardt, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.